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Introduction
Recombinant fusion protein linking recombinant coagulation 
factor IX with recombinant albumin (rIX-FP; Idelvion®†) is an 
innovative new treatment that was developed to extend the half-life 
of factor IX (FIX) and improve the lives of people with hemophilia 
B. The molecule was designed with a cleavable linker between 
the recombinant factor IX (rFIX) and the recombinant albumin 
moieties, allowing the fusion protein to benefit optimally from 
albumin’s long half-life, while preserving the function of the wild-
type coagulation factor [1,2]. The clinical development program 
for rIX-FP – PROLONG-9FP – was initiated in 2010 and is now in its 
advanced phases, with pivotal phase III studies in previously treated 
adults, adolescents, and pediatrics completed (Figure 1). A long-
term extension study is ongoing. This paper provides an update on 
the clinical development of rIX-FP for the treatment of patients with 
hemophilia B.
Phase I study of the safety and pharmacokinetics (PK) of rIX-FP 
in previously treated adults and adolescents with severe 
hemophilia B
This first-in-human study enrolled 25 previously treated adoles-
cents and adults (mean age 35 years; range 15–58 years) with severe 
hemophilia B (FIX activity ≤2%) and evaluated the safety and PK of 
single intravenous (IV) doses of rIX-FP at 25, 50, and 75 IU/kg when 
administered to patients in a non-bleeding state [3]. Patients who 
participated in the rIX-FP 50 IU/kg cohort also received a single 
50 IU/kg dose of their previous FIX treatment for PK assessments. 
The primary objective of the study was to assess the safety of 
rIX-FP based on the occurrence of adverse events (AEs), inhibitors 
against FIX, antibodies against rIX-FP, local tolerability, physical 
examinations and vital signs, urinalysis, and laboratory assessments.
The tolerability of rIX-FP was found to be excellent in this study. 
There were no hypersensitivity reactions and no patients developed 
inhibitors to FIX or antidrug antibodies [3]. Only four AEs were 
considered to be possibly related to rIX-FP (mild headache, feeling 
hot 50 minutes after the injection, mild constipation, and mild 
erythema at the injection site), all of which resolved on the same 
day without treatment.
This study was the first to demonstrate the remarkable PK 
profile of rIX-FP and generated considerable excitement amongst 







A B S T R A C T
Recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP; 
Idelvion®†) is an innovative new treatment designed to extend the half-life of factor IX (FIX) and ease the 
burden of care for hemophilia B patients. The rIX-FP clinical development program – PROLONG-9FP – is 
in its advanced phases, with pivotal studies in previously treated adults, adolescents, and pediatrics now 
completed. Across all age groups studied, rIX-FP has demonstrated a markedly improved pharmacokinetic 
profile compared with plasma-derived and recombinant FIX treatments, with a 30–40% higher incremental 
recovery, an approximately 5-fold longer half-life, a lower clearance, and a greater area under the curve. 
rIX-FP has been very well tolerated with an excellent safety profile. In the pivotal studies, there have been 
no reports of FIX inhibitors or antidrug antibodies, and few treatment-related adverse events have been 
observed. Prophylactic regimens of rIX-FP administered once weekly to once every 14 days have been highly 
effective. When used for surgical prophylaxis, a single infusion of rIX-FP has been sufficient to maintain 
hemostasis, even during major orthopedic surgery. An ongoing study is now enrolling previously untreated 
patients and evaluating the possibility of extending the dosing interval to every 21 days. There is little doubt 
that rIX-FP will transform the treatment of hemophilia B.
© 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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the hemophilia community. In the cohort of patients who received 
50 IU/kg of rIX-FP and 50 IU/kg of either plasma-derived FIX (pdFIX) 
or rFIX (BeneFIX®), the mean half-life of rIX-FP was 92 hours, which 
was more than 5-fold longer than that of rFIX and more than 
6-fold longer than that of pdFIX when used in the same patients. 
Importantly, mean FIX activity levels remained above 5% at the 
2-week (36 hours) PK assessment – an unprecedented finding. 
Compared with the other FIX treatments assessed in this study, 
rFIX-FP was also associated with a substantially reduced clearance 
and greater area under the curve.
Phase I/II study of the safety, efficacy, and PK of rIX-FP in previously 
treated adults and adolescents with severe hemophilia B
This phase I/II, open-label study was conducted to evaluate the 
safety, PK, and efficacy of rIX-FP when used for weekly prophylaxis 
and on demand for the treatment of bleeding episodes [4]. The 
study enrolled 17 previously treated patients (mean age 26 years; 
range 13–46 years) with severe hemophilia B (FIX activity ≤2%). All 
patients entered a 10–14-day PK evaluation period, followed by an 
11-month safety and efficacy evaluation period in which patients 
continued using rIX-FP either on demand (at a minimum dose of 
25 IU/kg) or as prophylaxis. Thirteen patients received prophylaxis 
with rIX-FP throughout the study (range 37–48 weeks); of these 13 
patients, three patients switched from an on-demand regimen with 
their previous FIX treatment to rIX-FP prophylaxis, and 10 patients 
continued prophylaxis but switched from their previous FIX product 
to rFIX-FP. Four patients switched from an on-demand regimen with 
their previous FIX treatment to rIX-FP on demand for the duration of 
the study (range 15–22 weeks).
The PK profile of the 25 IU/kg dose of rIX-FP was similar to that 
described in the phase I study. The mean incremental recovery of 
rIX-FP 25 IU/kg was 1.52 IU/dL per IU/kg, and the mean half-life 
was 94.8 hours [4]. The mean baseline-corrected FIX activity levels 
were 5.6% at Day 7 and 2.9% at Day 14 [4]. rIX-FP was well tolerated 
during a total exposure of over 700 days. None of the patients 
developed inhibitors to FIX or antibodies to rIX-FP. There were no 
hypersensitivity reactions and no significant treatment-emergent 
safety issues. None of the AEs reported were considered by the 
investigators to be related to rIX-FP, and no one withdrew from the 
study because of AEs.
The efficacy of rIX-FP was excellent when used as on-demand 
treatment and for prophylaxis [4]. A total of 85 bleeding episodes 
were treated with rIX-FP and all were treated successfully with 
one (95.3%) or two (4.7%) doses. Almost half (46%) of the patients 
receiving rIX-FP prophylaxis did not experience a single bleeding 
episode during this 11-month study [4].
Patients receiving rIX-FP prophylaxis experienced fewer spon-
taneous bleeding episodes than those receiving on-demand rIX-FP. 
A mean annualized spontaneous bleeding rate (AsBR) of 21.74 was 
reported for patients receiving rIX-FP on demand – a 20% reduction 
compared with their historical AsBR (Figure 2a). Patients receiving 
rIX-FP prophylaxis had a mean AsBR of 1.26 – a 50% reduction 
compared with their historical AsBR (Figure 2a). Most notably, 
however, patients switching from on-demand treatment with 
a previous FIX product to rIX-FP prophylaxis experienced a 95% 
reduction in AsBR (Figure 2a). Similar findings were observed for 
the total annualized bleeding rate (Figure 2b).
The results of this study confirmed that rIX-FP had an excellent 
safety and tolerability profile and that, as a result of its favorable PK 
profile, weekly prophylaxis was feasible and effective.
Phase II/III study of the efficacy and safety of rIX-FP in previously 
treated adults and adolescents with severe hemophilia B
The results of the pivotal phase II/III study of rIX-FP in previously 
treated adolescents and adults with severe hemophilia B (FIX activity 
≤2%) [5] have recently been presented [6,7]. The study was designed 
to evaluate the long-term efficacy and safety of rIX-FP when used 
on demand and in prophylactic regimens of every 7, 10, and 14 days 
(Figure 3). All patients initially participated in a 14-day PK evaluation 
period and received a single dose of rIX-FP 50 IU/kg. Patients were 
subsequently allocated to one of two treatment groups: Group 1 
received rIX-FP prophylaxis every 7 days for 6 months, then, where 
appropriate, the dosing interval could be extended to every 10 or 14 
days. Patients in Group 2 received rIX-FP on demand for 6 months, 
and then switched to prophylaxis every 7 days. The primary efficacy 
endpoint was the change in AsBR between on-demand and once-
weekly prophylaxis with rIX-FP, as assessed in study Group 2 [5].
A total of 63 patients took part in the study at centers in Europe, 
Japan, Israel, and the USA [7]. Nineteen patients switched from 
on-demand treatment with rIX-FP to weekly prophylaxis [7]. The 
median AsBR during rIX-FP on-demand treatment in this group 
of individuals was 15.43, which reduced to a median of 0.00 after 
switching to weekly rIX-FP prophylaxis – a highly statistically 
significant reduction of 100% (p<0.0001). Twenty-one patients 
extended their treatment interval to once every 14 days. The 
median AsBR amongst all prophylaxis patients on 7-, 10- and 14-
day regimens (n=40) was 0.00; rIX-FP administered every 14 days 
was as effective as once-weekly prophylaxis. Moreover, patients 
receiving rIX-FP prophylaxis every 14 days were able to reduce the 
consumption of their previous FIX product by 50% [7].
rIX-FP was also effective at treating bleeds in this study [7]. 
Overall, 98.6% of bleeds were successfully treated with ≤2 injections 
Fig. 1. PROLONG-9FP clinical program for evaluating the recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) in patients with 
severe hemophilia B. PK, pharmacokinetics; PUPs, previously untreated patients. Reproduced with permission from Schattauer GmbH: Swiss Medical Press GmbH. News from 
the XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Toronto, Canada. Pioneering therapeutic proteins in hemophilia care through innovative 
technologies. Thromb Haemost 2016;115:VI−X.
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of rIX-FP. rIX-FP demonstrated a favorable long-term tolerability and 
safety profile: no patient developed inhibitors to FIX or antidrug 
antibodies; there were no serious AEs considered to be related to 
treatment with rIX-FP, and no safety concerns emerged during the 
study [7].
Phase III surgical substudy of the efficacy of rIX-FP prophylaxis in 
patients undergoing non-emergency surgery
A surgical sub-study [8] was performed during the phase III 
study, with 10 patients undergoing 12 major surgeries – five of 
which were orthopedic procedures [9]. The hemostatic response, 
as rated by the investigators on a four-point scale, was excellent or 
good for all surgeries.
For patients undergoing orthopedic surgery, the median rIX-FP 
consumption was 87 IU/kg preoperatively, 51 IU/kg during post-
operative Days 1–2, and 340 IU/kg overall, which is low relative 
to other FIX replacement regimens used during surgery [9]. No 
inhibitors to FIX or antibodies to rIX-FP were detected and there 
were no AEs considered to be related to rIX-FP treatment.
Phase III study of the efficacy, PK, and safety of rIX-FP in 
previously treated pediatrics with severe hemophilia B
A phase III study evaluating the efficacy, PK, and safety of rIX-FP 
in 27 previously treated pediatrics (age <12 years) with severe 
hemophilia B (FIX activity ≤2%) has now been completed [10,11]. 
Following a 14-day PK analysis, patients received weekly prophylaxis 
with rIX-FP. The PK profile of rIX-FP was similar in the younger (aged 
1–5 years) and older (aged 6–11 years) pediatrics [6]. Compared with 
their previous FIX treatment, rIX-FP 50 IU/kg was associated with a 
higher incremental recovery and more than a five-fold longer half-
life, lower clearance, and greater area under the curve in this study. 
As expected, the incremental recovery of rIX-FP was slightly lower 
and clearance slightly higher in pediatrics compared with adults. 
After 14 days, plasma FIX activity levels remained at 3% in pediatrics, 
supporting a prolonged prophylaxis treatment interval [6].
Phase IIIb safety and efficacy extension study
This phase IIIb safety and efficacy extension study [12], which is 
currently ongoing, was designed for patients who had completed a 
previous study of rIX-FP in the treatment of hemophilia B and wished 
to continue treatment with rIX-FP. The study is also open to new 
previously treated patients scheduled to have non-emergency major 
surgery, and to previously untreated patients with documented 
severe hemophilia B. Additionally, a surgical prophylaxis substudy 
will examine the efficacy of rIX-FP in patients undergoing non-
emergency major or minor surgery.
Fig. 2. Annualized bleeding rate for prophylaxis with coagulation factor IX 
(recombinant), albumin fusion protein compared to historical bleeding rate. The mean 
annualized bleeding rate for spontaneous bleeds are shown in (a) and for all bleeds 
are shown in (b) [4]. The annualized bleeding rate for each patient was calculated as 
the number of bleeds during the time in treatment period of the study in days, divided 
by 365.25. The historical bleeding rate for each patient was the number of bleeds in 
the 12 month period prior to study entry. PT, prophylaxis treatment; ODT, on-demand 
treatment. Reproduced from Martinowitz et al. Results of a phase I/II open-label, safety 
and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in 
haemophilia B patients. Haemophilia 2015; 21(6): 784–790. CC-BY-NC-ND © 2015 CSL 
Behring.
Fig. 3. Design schematic for the PROLONG-9FP phase II/III study of the recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) in 
previously treated adults and pediatrics with severe hemophilia B. PK, pharmacokinetics.
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Conclusions
rIX-FP represents a significant advance in the management of 
hemophilia B that will ease the burden of treatment for patients 
of all ages. In prophylaxis, the opportunity to extend the dosing 
interval from every 3–4 days with currently available rFIX to up to 
every 14 days, or perhaps even longer, with rIX-FP, while, at the same 
time, reducing the number of spontaneous bleeds and improving 
joint health, is compelling. rIX-FP has also demonstrated excellent 
efficacy for the treatment of bleeding episodes and for surgical 
prophylaxis. Across all studies completed to date in all age groups, 
rIX-FP has been very well tolerated with a good safety profile. Based 
on its extended half-life and impressive clinical profile, there seems 
to be little doubt that rIX-FP will transform the treatment for many 
hemophilia B patients.
Abbreviations
AEs, adverse events; AsBR, annualized spontaneous bleeding 
rate; FIX, factor IX; IV, intravenous; pdFIX, plasma-derived factor IX; 
PK, pharmacokinetics; rFIX, recombinant factor IX; rIX-FP, recom-
binant fusion protein linking recombinant coagulation factor IX 
with recombinant albumin.
Conflict of interest
The author has received fees as a speaker in meetings organized 
by Kedrion, acted as a paid consultant to Bayer, Pfizer, CSL Behring, 
Novo Nordisk, Grifols, Baxter, Biogen/Idec, Sobi, Octapharma, and 
Roche, and received an unrestricted research grant from Pfizer.
References
 [1] Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin 
improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 
102: 634–644.
 [2] Schulte S. Half-life extension through albumin fusion technologies. Thromb Res 
2009; 124 (Suppl 2): S6–S9.
 [3] Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, et 
al. Safety and pharmacokinetics of a novel recombinant fusion protein linking 
coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 
120: 2405–2411.
 [4] Martinowitz U, Lissitchkov T, Lubetsky A, Jotov G, Barazani-Brutman T, Voigt C, et 
al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor 
IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia 
2015; 21(6): 784–790.
 [5] ClinicalTrials.gov. A safety and efficacy study of a recombinant fusion protein 
linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia 
B. https://clinicaltrials.gov/ct2/show/NCT01496274. Accessed 14 January 2016.
 [6] Santagostino E, Jacobs I, Voigt C, Feussner A, Limsakun T. Pharmacokinetic 
results of two phase III clinical studies of coagulation factor IX (recombinant) 
albumin fusion protein (rIX-FP) in previously treated patients with hemophilia B 
(PROLONG-9FP). Blood 2014; 124: 1491 (Abstract).
 [7] Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, 
Oldenburg J, et al. Efficacy and safety results of a phase 3 pivotal clinical study of 
recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) 
in previously treated patients with hemophilia B. J Thromb Haemost 2015; 13 
(Suppl 2): 228 (Abstract OR347).
 [8] ClinicalTrials.gov. A safety and efficacy extension study of a recombinant fusion 
protein linking coagulation factor IX with albumin (rIX-FP) in patients with 
hemophilia B. https://clinicaltrials.gov/ct2/show/NCT02053792?term=NCT0205
3792&rank=1. Accessed 14 January 2016.
 [9] Négrier C, Lepatan LM, Lubetsky A, Karim FA, Pan-Petesch B, Tagliaferri A, et al. 
Efficacy and safety of recombinant fusion protein linking coagulation factor IX 
with albumin (rIX-FP) in previously treated patients with hemophilia B undergo-
ing a surgical procedure. J Thromb Haemost 2015; 13 (Suppl 2): 843 (Abstract 
PO253-WED).
 [10] ClinicalTrials.gov. A safety, efficacy and pharmacokinetics study of a recombinant 
fusion protein linking coagulation factor IX with albumin (rIX-FP) in children 
with hemophilia B. https://clinicaltrials.gov/ct2/show/NCT01662531?term=NCT
01662531&rank=1. Accessed 14 January 2016.
 [11] Kenet G, Chambost H, Male C, Lambert T, Álvarez-Román M, Halimeh S, et al. 
Efficacy, pharmacokinetics (PK) and safety results of a phase 3 clinical study of 
recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) 
in previously treated children with hemophilia B. J Thromb Haemost 2015; 13 
(Suppl 2): 227 (Abstract OR346).
 [12] ClinicalTrials.gov. A pharmacokinetic, efficacy, and safety study of recombinant 
factor VIII single chain (rVIII-SingleChain) in children with severe hemophilia A. 
Available at: https://www.clinicaltrials.gov/ct2/show/NCT02093897?term=NCT0
2093897&rank=1. Accessed 14 January 2016.
